Drug Shortages: Causes and Coping

The Scope of Drug Shortages

Drug shortages are a persistent and growing challenge in the United States. The FDA's drug shortage database lists hundreds of active shortages at any given time, spanning cancer treatments, antibiotics, anesthetics, cardiovascular drugs, and everyday generic medications.

High-profile shortages in recent years have included:

• Amoxicillin and other pediatric antibiotics (2022–2023): A surge in respiratory illnesses combined with tight manufacturing capacity created nationwide shortages.
• Ozempic and Wegovy (semaglutide): Rapid demand growth for GLP-1 agonists in diabetes and obesity treatment outpaced manufacturing scale-up.
• Adderall (amphetamine salts): A combination of supply chain disruptions, manufacturing issues, and surging ADHD diagnosis rates created sustained shortages.
• Cisplatin and carboplatin: Critical chemotherapy agents experienced shortages that forced oncologists to alter treatment regimens for cancer patients.

For patients, a drug shortage can mean delayed treatment, anxiety about continuity of care, and sometimes substitution to a less familiar medication. For prescribers and pharmacists, shortages create complex clinical decisions and significant administrative burden.

Why Shortages Happen

No single cause explains drug shortages. The problem is systemic and involves several reinforcing factors.

Manufacturing Concentration Risk

Many generic drugs — particularly sterile injectables — are manufactured at a small number of facilities, often by a small number of companies. When one manufacturing site experiences a quality problem, natural disaster, fire, or equipment failure, it can remove a large fraction of the national supply in a single event. The US pharmaceutical supply chain has relatively little redundancy for low-margin generics.

The concentration problem is global: a significant proportion of active pharmaceutical ingredients (APIs) used in US drugs are produced in India and China. Disruptions in those supply chains — regulatory actions against foreign manufacturers, natural disasters, or geopolitical events — cascade directly into US shortages.

Economic Disincentives for Generic Manufacturers

Generic drugGeneric Drug

A medication that contains the same active ingredient, dosage form, strength, and route of administration as a brand-name drug, and has been demonstrated to be bioequivalent. Generic drugs can be mark

manufacturing for commonly used medications — particularly sterile injectables — operates on thin profit margins. Years of competitive price pressure among generic manufacturers have driven prices down to levels that leave little room for the facility investment, quality systems, and redundant capacity needed for supply resilience.

When a manufacturing problem forces a quality-related shutdown or recall, the economics of resuming production may not justify the capital cost of remediation. Older, off-patent drugs with low profit margins may simply be discontinued rather than repaired.

The perverse result: the drugs least likely to have manufacturer support (cheap generics, discontinued drugs) are precisely the drugs that end up in shortage.

Supply Chain Fragility

The COVID-19 pandemic exposed the extent to which pharmaceutical supply chains depend on just-in-time manufacturing and limited safety stock. Hospitals and wholesalers had been driven by efficiency pressures to minimize inventory. When demand surged or supply dropped, there was no buffer to draw on.

Beyond pandemic-era stress tests, the supply chain faces recurring vulnerabilities: raw material shortages, quality control failures triggering recalls (which reduce available supply), and demand spikes when a drug suddenly attracts new uses or population-level illness increases.

Which Drugs Are Most at Risk?

Drugs with the following characteristics are most vulnerable to shortage:

• Sterile injectables: Technically demanding to manufacture, produced at relatively few sites, required in hospitals for critical care
• Low-margin generics: Limited economic incentive for manufacturers to maintain redundant capacity
• Single-source products: Only one FDA-approved manufacturer
• Controlled substances: Additional regulatory requirements restrict manufacturer entry
• Drugs with surging demand: Demand growth that outpaces manufacturing investment (GLP-1 agonists being a recent example)

Brand-name drugs with patent protection and multiple manufacturing sites tend to be more resilient, as the manufacturer has economic incentive to maintain supply.

What Patients Can Do

When a medication you depend on is in shortage, a proactive approach helps:

1. Contact your pharmacy early: Pharmacies often have access to limited supplies before the shortage is widely recognized. Filling prescriptions earlier than your usual refill date (if your plan allows) can help secure existing inventory.

2. Ask your pharmacist which pharmacies have stock: Pharmacists often know their competitors' inventory situation and can direct you to a pharmacy with supply.

3. Ask your prescriber about a therapeutic alternative: For many conditions, a drug in the same class — a therapeutic substitutionTherapeutic Substitution

   Dispensing a different drug from the one prescribed, but within the same therapeutic class, when the prescribed drug is unavailable or for cost reasons. Unlike generic substitution (same drug, differe

   — can provide equivalent clinical benefit. For example, if one proton pump inhibitor is unavailable, another is likely available. Your prescriber and pharmacist can advise on appropriate substitutions for your situation.

4. Consider mail-order pharmacy: Mail-order pharmacies connected to large distribution networks sometimes have supply when local retail pharmacies do not.

5. Contact the manufacturer: Some manufacturers maintain patient access programs during shortages that give priority access to patients with documented medical need.

6. Check the FDA shortage database: The FDA's Drug Shortage Database (accessdata.fda.gov/scripts/drugshortages/) is updated regularly and includes estimated resolution timelines where available.

7. Document the shortage in your medical record: If a shortage forces a therapeutic substitution that results in worse outcomes, having a documented record matters for insurance appeals, disability claims, and future care.

What Prescribers and Pharmacists Can Do

Healthcare providers can take several steps to manage shortages responsibly:

• Implement therapeutic substitution protocols with explicit clinical guidance, so substitution decisions are consistent and well-documented.
• Communicate proactively with patients about shortages and the clinical rationale for any substitution.
• Prioritize the most vulnerable patients (e.g., cancer patients for chemotherapy shortage, patients with no alternative) when supply is limited.
• Report shortages to the FDA, which helps regulators prioritize their response.
• Avoid panic purchasing and hoarding, which worsens shortages by depleting supply for other patients.

Policy Solutions in Progress

Policymakers are increasingly focused on drug shortage resilience:

• FDA early warning requirements: Manufacturers are required to notify the FDA of anticipated interruptions in supply, giving earlier warning and time to coordinate alternative sources.
• DOGE / domestic API manufacturing: Policy interest in incentivizing domestic production of APIs and finished dosage forms to reduce dependence on single-country supply chains.
• Essential medicines inventory: Proposals for a strategic stockpile of critical medications — analogous to the Strategic Petroleum Reserve — to buffer against supply disruptions.
• Manufacturer reporting: Proposals to require manufacturers of critical drugs to maintain minimum days of supply in inventory.

Drug shortages reflect a systemic tension between the efficiency-driven logic of just-in-time global manufacturing and the public health imperative of resilient drug supply. Patients and providers coping with shortages today are experiencing the consequences of decades of supply chain decisions that optimized for cost over resilience.

This guide is for educational purposes only. It does not replace professional medical advice. Always consult your healthcare provider before making changes to your medication regimen.